이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Ekso Bionics Holdings 관리

관리 기준 확인 4/4

Ekso Bionics Holdings' CEO는 Scott Davis, Dec2022 에 임명되었습니다 의 임기는 1.5 년입니다. 총 연간 보상은 $ 637.02K, 58.9% 로 구성됩니다. 58.9% 급여 및 41.1% 보너스(회사 주식 및 옵션 포함). 는 € 96.91K 가치에 해당하는 회사 주식의 0.57% 직접 소유합니다. 96.91K. 경영진과 이사회의 평균 재임 기간은 각각 2.4 년과 3 년입니다.

주요 정보

Scott Davis

최고 경영자

US$637.0k

총 보상

CEO 급여 비율	58.9%
CEO 임기	1.8yrs
CEO 소유권	0.5%
경영진 평균 재임 기간	2.5yrs
이사회 평균 재임 기간	3.3yrs

최근 관리 업데이트

Recent updates

CEO 보상 분석

Scott Davis 의 보수는 Ekso Bionics Holdings 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Jun 30 2024	n/a	n/a	-US$12m
Mar 31 2024	n/a	n/a	-US$14m
Dec 31 2023	US$637k	US$375k	-US$15m
Sep 30 2023	n/a	n/a	-US$15m
Jun 30 2023	n/a	n/a	-US$16m
Mar 31 2023	n/a	n/a	-US$15m
Dec 31 2022	US$1m	US$370k	-US$15m

보상 대 시장: Scott 의 총 보상 ($USD 637.02K )은 German 시장에서 비슷한 규모의 회사의 평균 수준입니다( $USD 496.69K ).

보상과 수익: Scott 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.

CEO

Scott Davis (54 yo)

1.8yrs

테뉴어

US$637,020

보상

Mr. Scott G. Davis serves as Chief Executive Officer of Ekso Bionics Holdings, Inc. since December 04, 2022 and serves as Director since December 08, 2022, and also served as its President & Chief Operatin...

리더십 팀

이름	위치	테뉴어	보상	소유권
Scott Davis	CEO & Director	1.8yrs	US$637.02k	0.48% $ 98.5k
Jerome Wong	Chief Financial Officer	2.3yrs	US$726.08k	0.21% $ 42.7k
Jason Jones	Chief Operating Officer	1.8yrs	US$710.24k	0.22% $ 45.9k
Rachael Anderson	Global Director of Marketing & Strategic Growth	3.8yrs	데이터 없음	데이터 없음
Ann Cookson	Human Resources Director	2.5yrs	데이터 없음	데이터 없음
Foon Chwee	President of APAC	6.8yrs	데이터 없음	데이터 없음
Stephan Aderhold	Senior VP & GM of EMEA	2.8yrs	데이터 없음	데이터 없음

2.5yrs

평균 재임 기간

경험이 풍부한 관리: 23E2 의 관리팀은 경험 ( 2.4 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Scott Davis	CEO & Director	1.8yrs	US$637.02k	0.48% $ 98.5k
Sherri Medina	Member of Advisory Council	no data	데이터 없음	데이터 없음
Hans Keirstead	Member of Advisory Council	no data	데이터 없음	데이터 없음
Mary Cloyd	Independent Director	3.8yrs	US$147.01k	0.66% $ 134.8k
Corinna Lathan	Lead Independent Director	2.8yrs	US$158.13k	0.69% $ 140.2k
Nancy Byl	Member of Advisory Council	no data	데이터 없음	데이터 없음
Tom Kelley	Member of Advisory Council	no data	데이터 없음	데이터 없음
Daniel Kraft	Member of Advisory Council	no data	US$72.21k	데이터 없음
Kel Bergmann	Member of Advisory Council	no data	데이터 없음	데이터 없음
Graham Creasey	Member of Advisory Council	no data	데이터 없음	데이터 없음
Suzy Kim	Member of Advisory Council	no data	데이터 없음	데이터 없음
Charles Li	Independent Director	6.6yrs	US$143.10k	0.37% $ 75.0k

3.3yrs

평균 재임 기간

55yo

평균 연령

경험이 풍부한 이사회: 23E2 의 이사회는 경험(평균 재직 기간 3 년)으로 간주됩니다.

Ekso Bionics Holdings 관리

관리 기준 확인 4/4

주요 정보

최근 관리 업데이트

Ekso Bionics Holdings, Inc. Appoints Deborah Lafer Scher to its Board of Directors

Ekso Bionics Holdings, Inc., Annual General Meeting, Jun 06, 2024

Executive Chairman of the Board recently sold €61k worth of stock

High number of new and inexperienced directors

Ekso Bionics Holdings, Inc Announces Director Changes

Ekso Bionics Holdings, Inc. Approves Appointment of Jerome Wong as Corporate Secretary and Principal Financial Officer

Recent updates

New major risk - Shareholder dilution

Ekso Bionics Holdings, Inc. has completed a Composite Units Offering in the amount of $5.9971 million.

Ekso Bionics Holdings, Inc. has completed a Composite Units Offering in the amount of $6 million.

New major risk - Financial position

Forecast to breakeven in 2026

New minor risk - Profitability

Second quarter 2024 earnings released: US$0.13 loss per share (vs US$0.31 loss in 2Q 2023)

Ekso Bionics Holdings, Inc. has filed a Follow-on Equity Offering in the amount of $10 million.

Ekso Bionics Holdings, Inc. to Report Q2, 2024 Results on Jul 29, 2024

Ekso Bionics Holdings, Inc. Appoints Deborah Lafer Scher to its Board of Directors

Forecast to breakeven in 2026

First quarter 2024 earnings released: US$0.20 loss per share (vs US$0.33 loss in 1Q 2023)

Ekso Bionics Holdings, Inc., Annual General Meeting, Jun 06, 2024

Ekso Bionics Holdings, Inc. to Report Q1, 2024 Results on Apr 29, 2024

No longer forecast to breakeven

New minor risk - Profitability

Ekso Bionics Holdings, Inc. to Report Q4, 2023 Results on Mar 04, 2024

Forecast to breakeven in 2026

Ekso Bionics Holdings, Inc. has completed a Follow-on Equity Offering in the amount of $4.6 million.

Ekso Bionics Holdings, Inc. has filed a Follow-on Equity Offering in the amount of $4.6 million.

Ekso Bionics Holdings, Inc. has filed a Follow-on Equity Offering in the amount of $4.6 million.

Ekso Bionics Holdings, Inc. Launches GaitCoach Software for EksoNR

Ekso Bionics Holdings, Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year of 2023

Ekso Bionics Holdings, Inc. Receives CMS Coding Approval for Ekso Indego Personal

Third quarter 2023 earnings released: US$0.24 loss per share (vs US$0.33 loss in 3Q 2022)

Ekso Bionics Holdings, Inc. to Report Q3, 2023 Results on Oct 26, 2023

Ekso Bionics Holdings, Inc. Receives Non-Compliance Notice from Nasdaq

New major risk - Financial position

Second quarter 2023 earnings released: US$0.31 loss per share (vs US$0.23 loss in 2Q 2022)

Ekso Bionics Holdings, Inc. to Report Q2, 2023 Results on Jul 27, 2023

Executive Chairman of the Board recently sold €61k worth of stock

High number of new and inexperienced directors

No longer forecast to breakeven

Full year 2022 earnings released: US$1.16 loss per share (vs US$0.80 loss in FY 2021)

Forecast to breakeven in 2025

Ekso Bionics Holdings, Inc Announces Director Changes

Ekso Bionics Holdings, Inc. acquired Human Motion and Control Business Unit of Parker Hannifin Corporation for $10 million.

Third quarter 2022 earnings released: US$0.33 loss per share (vs US$0.15 loss in 3Q 2021)

Ekso Bionics Holdings, Inc. Approves Appointment of Jerome Wong as Corporate Secretary and Principal Financial Officer

Ekso Bionics Holdings, Inc. to Report Q3, 2022 Results on Nov 03, 2022

Second quarter 2022 earnings released: US$0.23 loss per share (vs US$0.10 loss in 2Q 2021)

Ekso Bionics Holdings, Inc. to Report Q2, 2022 Results on Jul 28, 2022

Ekso Bionics Holdings, Inc. Receives FDA Clearance to Market Its Eksonr(Tm) Robotic Exoskeleton for Use with Multiple Sclerosis Patients

Ekso Bionics Holdings, Inc. Announces Chief Financial Officer Changes

Ekso Bionics Holdings, Inc., Annual General Meeting, Jun 09, 2022

First quarter 2022 earnings released: US$0.36 loss per share (vs US$0.34 loss in 1Q 2021)

Ekso Bionics Holdings, Inc. to Report Q1, 2022 Results on Apr 28, 2022

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Ekso Bionics Holdings, Inc. to Report Q4, 2021 Results on Feb 24, 2022

Third quarter 2021 earnings released: US$0.15 loss per share (vs US$0.30 profit in 3Q 2020)

Second quarter 2021 earnings released: US$0.10 loss per share (vs US$1.88 loss in 2Q 2020)

First quarter 2021 earnings released: US$0.34 loss per share (vs US$0.44 loss in 1Q 2020)

Director has left the company

Full year 2020 earnings released: US$2.21 loss per share (vs US$2.53 loss in FY 2019)

Ekso Bionics Holdings, Inc., Annual General Meeting, Jun 10, 2021

Ekso Bionics Holdings, Inc. to Report Q4, 2020 Results on Feb 25, 2021

New 90-day high: €10.50

Ekso Bionics Holdings, Inc. Announces Resignation of Ted Wang as Member of the Board of Director

New 90-day high: €6.40

Ekso Bionics Holdings, Inc. Appoints Charles Li to its Board of Directors

New 90-day high: €6.35

New 90-day high: €5.00

New 90-day low: €3.58

Third-quarter earnings released: Revenue beats expectations

Third quarter earnings released

Ekso Bionics Holdings, Inc. Announces EGM Builders as First Customer to Adopt Evo Technology

New 90-day low: €3.60

Ekso Bionics Holdings, Inc. to Report Q2, 2020 Results on Jul 30, 2020

Ekso Bionics Holdings, Inc.(NasdaqCM:EKSO) dropped from Russell Microcap Growth Index